Implantable Therapeutic Device
First Claim
1. An ophthalmic drug delivery system comprising:
- an extended release device configured to be implanted in an eye, the device comprising;
a reservoir having a reservoir volume; and
a porous structure coupled to the reservoir, the porous structure having a release rate tuned to release a predetermined rate profile of a drug formulation from the reservoir and into the eye to treat the eye for an extended period of time; and
a drug formulation contained in and delivered by the extended release device, wherein the drug formulation comprises;
ranibizumab having a concentration in a solution volume and a given half-life upon bolus injection of the solution volume into the eye,wherein the extended release device is tuned to the drug formulation by selecting a value for at least one of the group consisting of;
the concentration, the reservoir volume, and the release rate, to achieve an effective half-life in the eye when the drug formulation is delivered by the implantable extended release device that is longer than the given half-life in the eye when the drug formulation is delivered by bolus injection.
1 Assignment
0 Petitions
Accused Products
Abstract
A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. The length of the channels extending from the first side to the second side may comprise an effective length greater than a distance across the porous structure from the first side to the second side. The therapeutic device may comprise a penetrable barrier to inject therapeutic agent into the device when implanted in the patient.
20 Citations
11 Claims
-
1. An ophthalmic drug delivery system comprising:
-
an extended release device configured to be implanted in an eye, the device comprising; a reservoir having a reservoir volume; and a porous structure coupled to the reservoir, the porous structure having a release rate tuned to release a predetermined rate profile of a drug formulation from the reservoir and into the eye to treat the eye for an extended period of time; and a drug formulation contained in and delivered by the extended release device, wherein the drug formulation comprises; ranibizumab having a concentration in a solution volume and a given half-life upon bolus injection of the solution volume into the eye, wherein the extended release device is tuned to the drug formulation by selecting a value for at least one of the group consisting of;
the concentration, the reservoir volume, and the release rate, to achieve an effective half-life in the eye when the drug formulation is delivered by the implantable extended release device that is longer than the given half-life in the eye when the drug formulation is delivered by bolus injection. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11)
-
Specification